|
Characteristic
|
Group 1
|
Group 2
|
|---|
|
n = 101
|
n = 22
|
|---|
|
Age at diagnosis,
|
|
(years); ±SD
|
36.9 ± 5.2
|
53.1 ± 4.8
|
|
Familial cancer
|
|
n (%)
|
54 (53%)
|
0
|
|
BMI,
|
|
mean; ±SD
|
27.7 ± 5.3
|
27.1 ± 4.2
|
|
Age at menarche
|
|
mean ± SD
|
12.3 ± 1.4
|
12.7 ± 1.3
|
|
Parity
|
|
mean ± SD
|
2.4 ± 1.6
|
3.6 ± 2.1
|
|
Nuliparous; n (%)
|
18 (18%)
|
1 (5%)
|
|
Age at first pregnancy
|
|
mean ± SD
|
21 ± 5.4
|
23 ± 5.6
|
|
Breastfeeding; n (%)
|
48/76 (63%)
|
11/20 (55%)
|
|
Contraceptive use; n (%)
|
38/97 (39%)
|
8/20 (40%)
|
|
Smoking; n (%)
|
17 (17%)
|
7 (32%)
|
|
Histology; n (%)
|
|
Ductal
|
80/90 (89%)
|
18/22 (82%)
|
|
Other
|
10/90 (11%)
|
4/22 (18%)
|
|
Nuclear Grade; n (%)
|
|
2
|
31/80 (39%)
|
18/21 (86%)
|
|
3
|
42/80 (53%)
|
2/21 (10%)
|
|
Stage; n (%)
|
|
0
|
1/101 (1%)
|
1. (0)
|
|
I–II
|
57/101 (56%)
|
17/22 (77)
|
|
III
|
39/101 (39%)
|
5/22 (23)
|
|
IV
|
4/101 (4%)
|
0 (0)
|
|
T; n (%)
|
|
0–1
|
29/100 (29%)
|
11/22 (50)
|
|
2
|
37/100 (37%)
|
7/22 (32)
|
|
3
|
25/100 (25%)
|
3/22 (14)
|
|
4
|
9/100 (9%)
|
1/22 (4)
|
|
N; n (%)
|
|
Positive
|
59/99 (60%)
|
12/22 (55%)
|
|
IHC; n (%)
|
|
ER (+)
|
52/95 (55%)
|
22/22 (100%)
|
|
PR (+)
|
47/95 (49%)
|
21/22 (95%)
|
|
HER (+)
|
19/93 (20%)
|
5/22 (23%)
|
|
Triple negative
|
30/93 (32%)
|
0 (0%)
|
|
Surgery type; n (%)
|
|
Radical mastectomy
|
80/99 (81%)
|
10/22 (45%)
|
|
Breast conservative
|
18/99 (18%)
|
12/22 (55%)
|
|
Chemotherapy; n (%)
|
|
Neoadjuvant
|
28/100 (28%)
|
4/22 (18%)
|
|
Adjuvant
|
62/100 (62%)
|
15/22 (68%)
|
|
Anthrac. based
|
9/62 (15%)
|
7/15 (40%)
|
|
Anthrac/Taxane.
|
45/62 (72%)
|
6/15 (47%)
|
- SD standard deviation, IHC immunohistochemical analysis, ER estrogen receptor, PR progesterone receptor; all means, and proportions were estimated for all the patients in each group, unless otherwise specified in the table
